In conclusion, myostatin dysfunction only increases the quantity, but does not negatively affect the quality of skeletal muscle fibers, holding promise for the application of myostatin inhibitors for the treatment of conditions associated with muscle wasting and weakness, such as Duchenne muscular dystrophy [2]. The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.